Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer’s disease in the UK using MMSE- and ADL-based models.


  1. Home


  2. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer’s disease in the UK using MMSE- and ADL-based models.


  3. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer’s disease in the UK using MMSE- and ADL-based models.

Nagy B, Brennan A, Brandtmüller A, Thomas SK, Sullivan SD, Akehurst R. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer’s disease in the UK using MMSE- and ADL-based models. Int J Geriatr Psychiatry. 2011 May;26(5):483-

Upcoming Events

Full Calendar


News Categories